BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 22522114)

  • 1. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples.
    Kotsakis A; Harasymczuk M; Schilling B; Georgoulias V; Argiris A; Whiteside TL
    J Immunol Methods; 2012 Jul; 381(1-2):14-22. PubMed ID: 22522114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer.
    Liu CY; Wang YM; Wang CL; Feng PH; Ko HW; Liu YH; Wu YC; Chu Y; Chung FT; Kuo CH; Lee KY; Lin SM; Lin HC; Wang CH; Yu CT; Kuo HP
    J Cancer Res Clin Oncol; 2010 Jan; 136(1):35-45. PubMed ID: 19572148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients.
    Vetsika EK; Koinis F; Gioulbasani M; Aggouraki D; Koutoulaki A; Skalidaki E; Mavroudis D; Georgoulias V; Kotsakis A
    J Immunol Res; 2014; 2014():659294. PubMed ID: 25436215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines.
    Lechner MG; Megiel C; Russell SM; Bingham B; Arger N; Woo T; Epstein AL
    J Transl Med; 2011 Jun; 9():90. PubMed ID: 21658270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-infiltrating and circulating granulocytic myeloid-derived suppressor cells correlate with disease activity and adverse clinical outcomes in mycosis fungoides.
    Argyropoulos KV; Pulitzer M; Perez S; Korkolopoulou P; Angelopoulou M; Baxevanis C; Palomba ML; Siakantaris M
    Clin Transl Oncol; 2020 Jul; 22(7):1059-1066. PubMed ID: 31696413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased Levels of Circulating Monocytic- and Early-Stage Myeloid-Derived Suppressor Cells (MDSC) in Acute Myeloid Leukemia.
    Lv J; Zhao Y; Zong H; Ma G; Wei X; Zhao Y
    Clin Lab; 2021 Mar; 67(3):. PubMed ID: 33739029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer.
    Eruslanov E; Neuberger M; Daurkin I; Perrin GQ; Algood C; Dahm P; Rosser C; Vieweg J; Gilbert SM; Kusmartsev S
    Int J Cancer; 2012 Mar; 130(5):1109-19. PubMed ID: 21480223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma.
    Zhang B; Wang Z; Wu L; Zhang M; Li W; Ding J; Zhu J; Wei H; Zhao K
    PLoS One; 2013; 8(2):e57114. PubMed ID: 23437326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells.
    Lechner MG; Liebertz DJ; Epstein AL
    J Immunol; 2010 Aug; 185(4):2273-84. PubMed ID: 20644162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Granulocytic myeloid-derived suppressor cells are cryosensitive and their frequency does not correlate with serum concentrations of colony-stimulating factors in head and neck cancer.
    Trellakis S; Bruderek K; Hütte J; Elian M; Hoffmann TK; Lang S; Brandau S
    Innate Immun; 2013 Jun; 19(3):328-36. PubMed ID: 23160385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD33
    Sun Y; Shao J; Jiang F; Wang Y; Yan Q; Yu N; Zhang J; Zhang J; Li M; He Y
    Am J Reprod Immunol; 2019 Jan; 81(1):e13067. PubMed ID: 30375700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma.
    Raychaudhuri B; Rayman P; Ireland J; Ko J; Rini B; Borden EC; Garcia J; Vogelbaum MA; Finke J
    Neuro Oncol; 2011 Jun; 13(6):591-9. PubMed ID: 21636707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Relevance and Suppressive Capacity of Human Myeloid-Derived Suppressor Cell Subsets.
    Lang S; Bruderek K; Kaspar C; Höing B; Kanaan O; Dominas N; Hussain T; Droege F; Eyth C; Hadaschik B; Brandau S
    Clin Cancer Res; 2018 Oct; 24(19):4834-4844. PubMed ID: 29914893
    [No Abstract]   [Full Text] [Related]  

  • 14. Healthy myeloid-derived suppressor cells express the surface ectoenzyme Vanin-2 (VNN2).
    Soler DC; Kerstetter-Fogle A; Young AB; Rayman P; Finke JH; Debanne SM; Cooper KD; Barnholtz-Sloan J; Sloan AE; McCormick TS
    Mol Immunol; 2022 Feb; 142():1-10. PubMed ID: 34953280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increase in both CD14-positive and CD15-positive myeloid-derived suppressor cell subpopulations in the blood of patients with glioma but predominance of CD15-positive myeloid-derived suppressor cells in glioma tissue.
    Gielen PR; Schulte BM; Kers-Rebel ED; Verrijp K; Petersen-Baltussen HM; ter Laan M; Wesseling P; Adema GJ
    J Neuropathol Exp Neurol; 2015 May; 74(5):390-400. PubMed ID: 25853692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppressive effects and mechanisms of three myeloid-derived suppressor cells subsets including monocytic-myeloid-derived suppressor cells, granulocytic-myeloid-derived suppressor cells, and immature-myeloid-derived suppressor cells.
    Nagatani Y; Funakoshi Y; Suto H; Imamura Y; Toyoda M; Kiyota N; Yamashita K; Minami H
    J Cancer Res Ther; 2021; 17(4):1093-1100. PubMed ID: 34528569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood CD33(+)HLA-DR(-) myeloid-derived suppressor cells are increased with age and a history of cancer.
    Verschoor CP; Johnstone J; Millar J; Dorrington MG; Habibagahi M; Lelic A; Loeb M; Bramson JL; Bowdish DM
    J Leukoc Biol; 2013 Apr; 93(4):633-7. PubMed ID: 23341539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies.
    Duffy A; Zhao F; Haile L; Gamrekelashvili J; Fioravanti S; Ma C; Kapanadze T; Compton K; Figg WD; Greten TF
    Cancer Immunol Immunother; 2013 Feb; 62(2):299-307. PubMed ID: 23011590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy.
    Chen HM; Ma G; Gildener-Leapman N; Eisenstein S; Coakley BA; Ozao J; Mandeli J; Divino C; Schwartz M; Sung M; Ferris R; Kao J; Wang LH; Pan PY; Ko EC; Chen SH
    Clin Cancer Res; 2015 Sep; 21(18):4073-4085. PubMed ID: 25922428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arginase-1 mRNA expression correlates with myeloid-derived suppressor cell levels in peripheral blood of NSCLC patients.
    Heuvers ME; Muskens F; Bezemer K; Lambers M; Dingemans AC; Groen HJM; Smit EF; Hoogsteden HC; Hegmans JPJJ; Aerts JGJV
    Lung Cancer; 2013 Sep; 81(3):468-474. PubMed ID: 23850196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.